Literature DB >> 32568661

Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 in Aerosol Suspensions.

Alyssa C Fears, William B Klimstra, Paul Duprex, Amy Hartman, Scott C Weaver, Kenneth S Plante, Divya Mirchandani, Jessica Ann Plante, Patricia V Aguilar, Diana Fernández, Aysegul Nalca, Aysegul Totura, David Dyer, Brian Kearney, Matthew Lackemeyer, J Kyle Bohannon, Reed Johnson, Robert F Garry, Doug S Reed, Chad J Roy.   

Abstract

We aerosolized severe acute respiratory syndrome coronavirus 2 and determined that its dynamic aerosol efficiency surpassed those of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome. Although we performed experiment only once across several laboratories, our findings suggest retained infectivity and virion integrity for up to 16 hours in respirable-sized aerosols.

Entities:  

Keywords:  2019 novel coronavirus disease; COVID-19; MERS-CoV; Middle East respiratory syndrome coronavirus; SARS-CoV; SARS-CoV-2; aerosol; coronavirus diseases; respiratory diseases; severe acute respiratory syndrome coronavirus; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses

Mesh:

Substances:

Year:  2020        PMID: 32568661      PMCID: PMC7454081          DOI: 10.3201/eid2609.201806

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a readily transmissible zoonotic pathogen and the etiologic agent of the coronavirus disease (COVID-19) pandemic (). To determine aerosol stability of the virus, we measured the dynamic (short-term) aerosol efficiencies of SARS-CoV-2 and compared its efficiency with SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV).

The Study

We analyzed these 3 viruses’ dynamic aerosol efficiencies using 3 nebulizers: the Collison 3-jet (C3), Collison 6-jet (C6) (www.chtechusa.com), and Aerogen Solo (AS) (https://www.aerogen.com), to generate viral aerosols (Appendix). We performed comparative efficiency experiments once in each of 4 aerobiology laboratories (Tulane University, New Orleans, LA, USA; National Institutes of Health Integrated Research Facility [NIH-IRF], Fort Detrick, MD, USA; US Army Medical Institute for Infectious Diseases, Fort Detrick, MD, USA; and University of Pittsburgh, Pittsburgh, PA, USA). The aerosol size distributions produced by the generators used, in mass median aerodynamic diameter, were 1–3 μm and had a geometric heterodispersity of ≈1.2–1.4. Aerosols were generated into 16-liter primate head-only exposure chambers (MERS-CoV or SARS-CoV-2) or a 30-liter rodent chamber (SARS-CoV), where the overall flow was ≈1 (Tulane University) or 0.5 (NIH-IRF, US Army Medical Research Institute of Infectious Diseases, University of Pittsburgh) air changes per minute. Use chamber and corresponding flow rates enabled us to determine the dynamic efficiencies of the virus in aerosols during a short residence time. Samples were continuously collected and integrated throughout the initiation of respective nebulizers into the chamber during aerosol generation events of 10–30 min. We calculated the dynamic aerosol efficiency or spray factor (Fs) as a unitless quotient of initial titer (PFU/L in liquid stock) to the resulting aerosol (PFU/L aerosol) providing a quantitative indicator for comparing airborne fitness (,). We determined Fs for all 3 viruses after <1 min of chamber residence after aerosolization (Figure 1). When we compared both MERS-CoV and SARS-CoV to SARS-CoV-2 aerosols generated with a C3 nebulizer across 3 laboratories, we noted a small but significant improvement in Fs for SARS-CoV-2 but not for SARS-CoV (p = 0.02) or MERS-CoV (p = 0.01). Because SARS-CoV was aerosolized into a different chamber/volume than MERS-CoV and SARS-CoV-2, we cannot rule out chamber effects for the difference in Fs between SARS-CoV and SARS-CoV-2. Our comparison of nebulizers showed improved Fs for SARS-CoV-2 with the C6 (p = 0.006) and the AS (p = 0.01) over the C3 but no difference between the C6 and AS (p = 0.46).
Figure 1

Aerosol efficiency of MERS-CoV, SARS-CoV and SARS-CoV-2 at different sites. Graph shows the spray factor (i.e., ratio of nebulizer concentration to aerosol concentration) for MERS-CoV (red), SARS-CoV (blue), and SARS-CoV2 (green). Aerosols were performed at 4 sites and with different nebulizers. AS, Aerogen Solo nebulizer; C3, Collison 3-jet nebulizer; C6, Collison 6-jet nebulizer; MERS-Cov, Middle East respiratory syndrome coronavirus; S1, Tulane University, New Orleans, LA, USA; S2, National Institutes of Health Integrated Research Facility, Fort Detrick, MD, USA; S3, US Army Medical Institute for Infectious Diseases, Fort Detrick, MD, USA; S4, University of Pittsburgh, Pittsburgh, PA, USA; SARS-CoV, severe acute respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Aerosol efficiency of MERS-CoV, SARS-CoV and SARS-CoV-2 at different sites. Graph shows the spray factor (i.e., ratio of nebulizer concentration to aerosol concentration) for MERS-CoV (red), SARS-CoV (blue), and SARS-CoV2 (green). Aerosols were performed at 4 sites and with different nebulizers. AS, Aerogen Solo nebulizer; C3, Collison 3-jet nebulizer; C6, Collison 6-jet nebulizer; MERS-Cov, Middle East respiratory syndrome coronavirus; S1, Tulane University, New Orleans, LA, USA; S2, National Institutes of Health Integrated Research Facility, Fort Detrick, MD, USA; S3, US Army Medical Institute for Infectious Diseases, Fort Detrick, MD, USA; S4, University of Pittsburgh, Pittsburgh, PA, USA; SARS-CoV, severe acute respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. Further studies with SARS-CoV-2 at Tulane University preliminarily assessed the long-term stability of airborne virus. We used a custom-built rotating (Goldberg) drum to provide an environment in which rotational drum speed overcomes the terminal settling velocity of the 2–3-μm particles, thereby providing a static aerosol suspension of known volume (–). We timed aerosol samples from the drum at 10 min and 30 min and at 2 h, 4 h, and 16 h after initiation of rotation/suspension. The entire drum volume (10.7 L) was evacuated at each sampling interval and represented a discrete aerosol generation event. We quantified virus contents by plaque assay and reverse transcription quantitative PCR (RT-qPCR). We also conducted scanning electron microscopy on the collected aerosol samples as a complimentary qualitative assessment of virion integrity after longer-term aerosol suspension (Appendix). We measured environmental parameters but did not control them during the aerosol suspension experiments. The prevailing ambient environmental conditions were 23°C ± SD 2°C and 53% ± SD 11% relative humidity throughout the aerosol stability experiments. No ultraviolet light source was used within the cavity of the drum during suspensions. After initial generation of viral bioaerosols into the drum reached steady-state concentration, the drum was sealed and maintained as a static aerosol. We conducted all sampling time points once in this set of experiments. We graphed plaque assay and RT-qPCR results and applied nonlinear least-squares regression analysis single-order decay with no outlier detection, resulting in a poor curve fit, which typically results from a lack of replicate samples. We detected infectious SARS-CoV-2 at all time points during the aerosol suspension stability experiment (Figure 2). A minor but constant fraction of SARS-CoV-2 maintained replication-competence at all time points (Figure 2, panel A), including when sampled after 16 h of aerosol suspension. This finding resulted in a remarkably flat decay curve when measured for infectivity and failed to provide a biologic half-life (κ = 2.93E-06; t1/2 = 2.36E+05; τ = 3.40E+05). The curve (Figure 2, panel B) from the results of split sample analysis as quantified by RT-qPCR showed minimal decreases in aerosol concentration measured in viral genome copies across all of time points sampled and approximated the decay curve of the infectious virus fraction (Figure 2, panel A), including similar decay curve characteristics (κ = 6.19E-03; t1/2 = 111.9; τ = 161.4).
Figure 2

Decay curves of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in aerosol suspension. A) Aerosol concentration of infectious SARS-CoV-2 as measured by plaque assay found in impinger samples collected at 5 time points of increased aging in aerosol suspension. B) Corresponding aerosol concentration of SARS-CoV-2 in time-matched impinger samples as a function of viral genome copies as measured by reverse transcription quantitative PCR. Both time point virus estimates were graphed, and nonlinear least-squares regression analysis single-order decay with no outlier detection was performed, resulting in a poor curve fit by either method of viral quantitation resulting from number and lack of iterative samples in this analysis.

Decay curves of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in aerosol suspension. A) Aerosol concentration of infectious SARS-CoV-2 as measured by plaque assay found in impinger samples collected at 5 time points of increased aging in aerosol suspension. B) Corresponding aerosol concentration of SARS-CoV-2 in time-matched impinger samples as a function of viral genome copies as measured by reverse transcription quantitative PCR. Both time point virus estimates were graphed, and nonlinear least-squares regression analysis single-order decay with no outlier detection was performed, resulting in a poor curve fit by either method of viral quantitation resulting from number and lack of iterative samples in this analysis. We also performed a qualitative assessment of virion integrity after longer-term aerosol suspension (Appendix). Scanning electron microscopy (SEM) imaging of SARS-CoV-2 revealed virions that were heterogeneous in shape, either ovoid (Appendix Figure, panel A) or spherical (Appendix Figure, panel B). The minor:major axis ratio of oval virions was ≈0.7, which is consistent with prior SEM analyses of SARS-CoV-2 (https://www.flickr.com/photos/niaid/albums/72157712914621487). Airborne SARS-CoV-2 maintained the expected morphologies, size, and aspect ratios up to 16 h. Specifically, virions aged for 10 min (Appendix Figure, panels C, D) or 16 h (Appendix Figures, panels E, F) were similar in shape and general appearance to virions examined in samples of viral inoculum collected before aerosolization, which is consistent with the retention of replication-competence and suggests the potential to be infectious after long-term aging in aerosol suspension.

Conclusions

The comparison of short-term aerosol efficiencies of 3 coronaviruses showed SARS-CoV-2 approximates or exceeds the efficiency estimates of SARS-CoV and MERS-CoV. Some efficiency determinations for SARS-CoV-2 ranged to −5.5log10 (Figure 1), a full log difference from MERS-CoV. The higher efficiencies across independent laboratories strengthens this observation. These data suggest that SARS-CoV-2 generally maintains infectivity at a respirable particle size over short distances, in contrast to either betacoronavirus. Aerosol suspension results suggest that SARS-CoV-2 persists longer than would be expected when generated as this size particle (2-µm mass median aerodynamic diameter). This finding is notable because decay and loss in the infectious fraction of airborne virus would be expected on the basis of prior susceptibility studies with other environmentally hardy viruses, such as monkeypox virus (). A recent study () showing only a slight reduction of infectivity in aerosol suspensions with approximately similar particle sizes also suggested minimal effects on SARS-CoV-2 airborne degradation. Collectively, these preliminary data suggest that SARS-CoV-2 is resilient in aerosol form and agree with conclusions reached in earlier studies of aerosol fitness (). A clear limitation of the aerosol stability data is that we report only 1 measurement of the 16-h time point; future studies need to repeat these findings before any definitive conclusions are reached. Aerosol transmission of SARS-CoV-2 may be a more important exposure transmission pathway than previously considered (). Our approach of quantitative measurement of infectivity of viral airborne efficiency augmented by assessment of virion morphology suggests that SARS-CoV-2 may be viable as an airborne pathogen. Humans produce aerosols continuously through normal respiration (). Aerosol production increases during respiratory illnesses (,) and during louder-than-normal oration (). A fraction of naturally generated aerosols falls within the size distribution used in our experimental studies (<5 μm), which leads us to conclude that SARS-CoV-2–infected persons may produce viral bioaerosols that remain infectious for long periods after production through human shedding and airborne transport. Accordingly, our study results provide a preliminary basis for broader recognition of the unique aerobiology of SARS-CoV-2, which might lead to tractable solutions and prevention interventions.

Appendix

Additional methods and results in a study of aerosol efficiencies of coronaviruses.
  11 in total

1.  The use of a rotating drum for the study of aerosols over extended periods of time.

Authors:  L J GOLDBERG; H M WATKINS; E E BOERKE; M A CHATIGNY
Journal:  Am J Hyg       Date:  1958-07

2.  Development, Characterization, and Standardization of a Nose-Only Inhalation Exposure System for Exposure of Rabbits to Small-Particle Aerosols Containing Francisella tularensis.

Authors:  Katherine J O'Malley; Jennifer D Bowling; Eileen M Barry; Karsten R O Hazlett; Douglas S Reed
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

3.  Dynamics of Cough Frequency in Adults Undergoing Treatment for Pulmonary Tuberculosis.

Authors:  Alvaro Proaño; Marjory A Bravard; José W López; Gwenyth O Lee; David Bui; Sumona Datta; Germán Comina; Mirko Zimic; Jorge Coronel; Luz Caviedes; José L Cabrera; Antonio Salas; Eduardo Ticona; Nancy M Vu; Daniela E Kirwan; Maria-Cristina I Loader; Jon S Friedland; David A J Moore; Carlton A Evans; Brian H Tracey; Robert H Gilman
Journal:  Clin Infect Dis       Date:  2017-05-01       Impact factor: 9.079

4.  The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission.

Authors:  Valentyn Stadnytskyi; Christina E Bax; Adriaan Bax; Philip Anfinrud
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-13       Impact factor: 11.205

5.  Infectious disease aerobiology: miasma incarnate.

Authors:  Chad J Roy; Doug S Reed
Journal:  Front Cell Infect Microbiol       Date:  2012-12-19       Impact factor: 5.293

6.  Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures.

Authors:  Rachael Pung; Calvin J Chiew; Barnaby E Young; Sarah Chin; Mark I-C Chen; Hannah E Clapham; Alex R Cook; Sebastian Maurer-Stroh; Matthias P H S Toh; Cuiqin Poh; Mabel Low; Joshua Lum; Valerie T J Koh; Tze M Mak; Lin Cui; Raymond V T P Lin; Derrick Heng; Yee-Sin Leo; David C Lye; Vernon J M Lee
Journal:  Lancet       Date:  2020-03-17       Impact factor: 79.321

Review 7.  SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat.

Authors:  Jun Zheng
Journal:  Int J Biol Sci       Date:  2020-03-15       Impact factor: 6.580

8.  Airborne transmission of SARS-CoV-2: The world should face the reality.

Authors:  Lidia Morawska; Junji Cao
Journal:  Environ Int       Date:  2020-04-10       Impact factor: 9.621

9.  Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.

Authors:  Neeltje van Doremalen; Trenton Bushmaker; Dylan H Morris; Myndi G Holbrook; Amandine Gamble; Brandi N Williamson; Azaibi Tamin; Jennifer L Harcourt; Natalie J Thornburg; Susan I Gerber; James O Lloyd-Smith; Emmie de Wit; Vincent J Munster
Journal:  N Engl J Med       Date:  2020-03-17       Impact factor: 91.245

10.  Estimation of airborne viral emission: Quanta emission rate of SARS-CoV-2 for infection risk assessment.

Authors:  G Buonanno; L Stabile; L Morawska
Journal:  Environ Int       Date:  2020-05-11       Impact factor: 9.621

View more
  95 in total

1.  Mounting evidence suggests coronavirus is airborne - but health advice has not caught up.

Authors:  Dyani Lewis
Journal:  Nature       Date:  2020-07       Impact factor: 49.962

2.  Particle Dynamics and Bioaerosol Viability of Aerosolized Bacillus Calmette-Guérin Vaccine Using Jet and Vibrating Mesh Clinical Nebulizers.

Authors:  Rachel K Redmann; Deepak Kaushal; Nadia Golden; Breeanna Threeton; Stephanie Z Killeen; Philip J Kuehl; Chad J Roy
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2021-10-06       Impact factor: 2.849

3.  Interim recommendations for the management of forensic investigation during the COVID-19 pandemic: An Italian perspective.

Authors:  Enrico Di Luise; Paola A Magni
Journal:  Sci Justice       Date:  2021-08-19       Impact factor: 2.124

4.  Investigation of SARS-CoV-2 in hospital indoor air of COVID-19 patients' ward with impinger method.

Authors:  Mehdi Vosoughi; Chiman Karami; Abdollah Dargahi; Farhad Jeddi; Kamyar Mazloum Jalali; Aidin Hadisi; Somayeh Biparva Haghighi; Hadi Peeri Dogahe; Zahra Noorimotlagh; Seyyed Abbas Mirzaee
Journal:  Environ Sci Pollut Res Int       Date:  2021-05-06       Impact factor: 4.223

5.  Wind tunnel-based testing of a photoelectrochemical oxidative filter-based air purification unit in coronavirus and influenza aerosol removal and inactivation.

Authors:  Yuechen Qiao; My Yang; Ian A Marabella; Devin A J McGee; Bernard A Olson; Montserrat Torremorell; Christopher J Hogan
Journal:  Indoor Air       Date:  2021-05-07       Impact factor: 6.554

6.  Commentary: Inhale, exhale - Fighting the invisible enemy with every breath!

Authors:  Anthony Vipin Das
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

7.  The outcomes and acceptance of pressurized metered-dose inhaler bronchodilators with venturi mask modified spacer in the outpatient emergency department during the COVID-19 pandemic.

Authors:  Hock Peng Koh; Nurul Shaliza Shamsudin; Marilyn May Yeen Tan; Zulsairi Mohd Pauzi
Journal:  J Clin Pharm Ther       Date:  2021-03-25       Impact factor: 2.145

8.  Natural ventilation strategy and related issues to prevent coronavirus disease 2019 (COVID-19) airborne transmission in a school building.

Authors:  Sowoo Park; Younhee Choi; Doosam Song; Eun Kyung Kim
Journal:  Sci Total Environ       Date:  2021-05-15       Impact factor: 7.963

Review 9.  SARS-CoV-2-Morphology, Transmission and Diagnosis during Pandemic, Review with Element of Meta-Analysis.

Authors:  Katarzyna Grudlewska-Buda; Natalia Wiktorczyk-Kapischke; Ewa Wałecka-Zacharska; Joanna Kwiecińska-Piróg; Katarzyna Buszko; Kamil Leis; Klaudia Juszczuk; Eugenia Gospodarek-Komkowska; Krzysztof Skowron
Journal:  J Clin Med       Date:  2021-05-03       Impact factor: 4.241

Review 10.  Recent research on expiratory particles in respiratory viral infection and control strategies: A review.

Authors:  Yunchen Bu; Ryozo Ooka; Hideki Kikumoto; Wonseok Oh
Journal:  Sustain Cities Soc       Date:  2021-06-18       Impact factor: 7.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.